晨化股份(300610.SZ):全資子公司獲得《江蘇省投資項目備案證》
格隆匯11月27日丨晨化股份(300610.SZ)公佈,近日,公司全資子公司淮安晨化新材料有限公司(以下簡稱"淮安晨化")收到淮安市工業和信息化局簽發的《江蘇省投資項目備案證》【備案證號:淮工信備〔2024〕23號】。淮安晨化新材料有限公司年產35,000噸烷基糖苷擴建項目(以下簡稱"本項目")尚處於前期備案階段,本項目在正式實施前尚需經過公司董事會、股東大會審議,能否按計劃進行投資建設具有不確定性;相關政府部門土地使用權、審批手續尚在辦理中。受國家政策法規、政府機構審批進度、公司資金狀況及公司審批流程等多種因素影響,本項目開工建設時間、具體實施進度等均存在一定的不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.